Che Qi, Schreiber Martin J, Rafey Mohammed A
Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Cleve Clin J Med. 2009 Sep;76(9):533-42. doi: 10.3949/ccjm.76a.09030.
Although beta-blockers lower blood pressure in most patients, the outcomes of clinical hypertension trials of these drugs have been disappointing, and the value of beta-blockers in treating hypertensive patients who do not have compelling indications for them has been questioned. Until these drugs are proved beneficial, they should be used as antihypertensive therapy only in patients with compelling cardiac indications for them or as add-on agents in those with uncontrolled or resistant hypertension.
尽管β受体阻滞剂能降低大多数患者的血压，但这些药物在临床高血压试验中的结果却令人失望，而且β受体阻滞剂在治疗无明确使用指征的高血压患者中的价值也受到了质疑。在这些药物被证明有益之前，它们仅应用于有明确心脏指征的患者作为抗高血压治疗，或用于血压控制不佳或顽固性高血压患者作为附加药物。
